Quality of informed consent in cancer clinical trials: a cross-sectional survey

Investigators have to obtain informed consent before enrolling participants in clinical trials. We wanted to measure the quality of understanding among participants in clinical trials of cancer therapies, to identify correlates of increased understanding, and to assess providers' beliefs about...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2001-11, Vol.358 (9295), p.1772-1777
Main Authors: Joffe, Steven, Cook, E Francis, Cleary, Paul D, Clark, Jeffrey W, Weeks, Jane C
Format: Article
Language:English
Subjects:
Adult
Aged
Attitude to Health
Bioethics
Cancer
Clinical trials
Clinical Trials as Topic
Comprehension
Disclosure
Female
Humans
Informed Consent
Male
Middle Aged
Neoplasms - drug therapy
Physician-Patient Relations
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Investigators have to obtain informed consent before enrolling participants in clinical trials. We wanted to measure the quality of understanding among participants in clinical trials of cancer therapies, to identify correlates of increased understanding, and to assess providers' beliefs about clinical research. We also sought evidence of therapeutic misconceptions in participants and providers. We sent a standard questionnaire to 287 adult patients with cancer who had recently enrolled in a clinical trial at one of three affiliated institutions, and surveyed the provider who obtained each patient's consent. 207 of 287 (72%) patients responded. 90% (186) of these respondents were satisfied with the informed consent process and most considered themselves to be well informed. Nevertheless, many did not recognise non-standard treatment (74%), the potential for incremental risk from participation (63%), the unproven nature of the treatment (70%), the uncertainty of benefits to self (29%), or that trials are done mainly to benefit future patients (25%). In multivariate analysis, increased knowledge was associated with college education, speaking only English at home, use of the US National Cancer Institute consent form template, not signing the consent form at initial discussion, presence of a nurse, and careful reading of the consent form. Only 28 of 61 providers (46%) recognised that the main reason for clinical trials is benefit to future patients. Misconceptions about cancer clinical trials are frequent among trial participants, and physician/investigators might share some of these misconceptions. Efforts to educate providers and participants about the underlying goals of clinical trials are needed.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(01)06805-2